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ABSTRACT 
 
in vivo Evaluation of Bone Regeneration  
by TAT-BMP-2 and Hydrogel Composite  
 
 
Son, Kyooho 
Department of Dentistry 
The Graduate School, Yonsei University 
(Directed by Professor Jong In Yook, D.D.S., Ph.D.) 
 
Although the need for bone regeneration is gradually increasing due to aging, 
alveolar bone loss, and osteoporosis, clinical modality is not yet definite. Exogenous 
bone morphogenetic protein (BMP) should have sufficient bioactivity and be in 
harmony with carriers by controlled release of biological factors with mechanical 
support. Recombinant human BMP-2 (rhBMP-2) are currently used in clinics, but their 
efficacy remains obscure. 
Contrary to rhBMP-2, inactive polypeptide TAT-BMP-2 fusion protein can be 
successfully transduced into cells in concentration- and time-dependent manners 
independent to BMP receptors. Hydrogel, which is made of hyaluronic acid, one of the 
major components of human connective tissue, shows biocompatibility and releases 
containing materials in a controlled manner with degradation. This study aims to evaluate 
 v 
 
bone regeneration radiologically and histologically with the femurs of beagles by 
combining TAT-BMP-2 with fibrin, hydrogel, and PEEK. The results are as follows: 
 
1. TAT-BMP-2 fibrin composite induced superior bone regeneration than the fibrin-only 
applied subject under isolated condition by PEEK, but statistically not significant. 
2. The application of hydrogel alone induced partial bone regeneration. 
3. TAT-BMP-2 hydrogel composite caused superior bone regeneration than the application 
of hydrogel alone in area, volume analysis (p<0.05). 
4. TAT-BMP-2 hydrogel composite only induced regeneration of continuity of the outer 
cortex and showed a more matured, dense structure than the application of hydrogel 
alone. 
5. TAT-BMP-2 hydrogel composite decreased dosage for in vivo bone regeneration by 
1/1000 of the conventional dosage of rhBMP-2. 
 
These results indicate that TAT-BMP-2 hydrogel composite induced effective in vivo 
bone regeneration by highly efficient protein synthesis through inactive polypeptide TAT-
BMP-2 as well as controlled protein releasing through hydrogel. 
 
 
 
 
Key words: PTD (Protein Transduction Domian), HIV-1 TAT, BMP (Bone Morphogenetic 
Protein), hydrogel  
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I. INTRODUCTION 
 
Attempts to induce de novo bone formation are among the most interesting 
experiments in clinics. Although the need for bone repair and replacement is gradually 
increasing due to aging, trauma, and tumors, this field still remains a significant challenge. 
Tissue engineering for bone regeneration can be described as a combination of biological, 
chemical, and engineering principles toward the repair, restoration, and replacement of 
tissues using cells, scaffolds, and biologic factors alone or in harmonious combination 
(Laurencin et al., 2006).  
For successful bone regeneration, osteoprogenitor cells should be differentiated into 
osteoblast by several growth factors, of which bone morphogenetic protein (BMP) plays a 
major role(Li and Wozney, 2001). BMPs are members of the transforming growth factor-
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beta superfamily and elicit cellular effects through the induction of heteromeric 
complexes of type I and type II serine/threonine receptors (Massague et al., 1992; Wrana 
et al., 1994). Approximately twenty different members of the BMP super group have been 
identified. However, only a subset is able to singly promote osteoinduction, including 
BMP-2 through -7 and BMP-9 (Abe, 2006; El-Amin et al., 2010; Termaat et al., 2005). 
Thanks to notable advances in molecular biology since discovering BMP in decalcified 
bone that induces differentiation of undifferentiated mesenchymal cells into osteoblast 
(Urist, 1965), human BMP genes have been identified and cloned. Now, recombinant 
rhBMP-2 are produced and purified from E.Coli and mammalian cell lines, but their in 
vivo efficacy is still unclear and needs more study. 
To amplify the regeneration efficacy of exogenous BMPs, protein transduction 
domain (PTD), which delivers passenger protein directly to intracellular space, can be 
considered. The function of PTDs was discovered from human immunodeficiency virus 
(HIV)-1 trans-activator of transcription (TAT) protein that enters into cytoplasm in a 
concentration-dependent manner without going through any receptor system (Frankel and 
Pabo, 1988; Green and Loewenstein, 1988). HIV-1 TAT fusion protein consists of 86 
amino acids, including two essential exons to replicate HIV. Eleven of the amino acids 
(RKKRRQRRR) are known to regulate unrestricted protein transduction (Schwarze et al., 
2000). However, exact transduction mechanisms have not yet been announced.  
To acquire successful in vivo bone regeneration, the function of carrier and the 
efficiency of BMP itself are important (Lo et al., 2012). Hyaluronic acid (HA) is one of 
the major components of the extracellular matrix and is found in all connective tissues of 
the body. It is a naturally derived, linear, high molecular weight polymer with visco-
 3 
 
elastic properties (Laurent et al., 1995). Due to its visco-elastic properties and biological 
functions, HA has been used predominantly as a raw material for hydrogel (Prestwich et 
al., 1998; Vercruysse and Prestwich, 1998). Hydrogel is a hydrophilic, biocompatible 
material that is able to induce osteoinduction, shows the controlled release of containing 
drugs, and degrades without foreign body reaction.  
Fibrin is a material that can be rapidly invaded, remodeled, and replaced by cell-
associated proteolytic activity (Murphy and Gavrilovic, 1999). Although there are 
conflicts concerning the use of fibrin for in vivo bone regeneration application (Patel et al., 
2006), fibrin can be recognized as a proper carrier material in bone regeneration (Yang et 
al., 2010). 
Poly ether ether ketone (PEEK) is a biocompatible polymer consisting of calcium 
phosphate and collagen that can be applied in spinal fusion where mechanical resistance 
is needed (Boakye et al., 2005; Meisel et al., 2008). Also PEEK's isolating ability of 
containing materials from external environment helps evaluating regeneration capacity of 
entrapped material. 
For an ideal in vivo bone regeneration, regenerative medicine should be released in a 
controlled manner during scaffold degradation to permit complete repair by the host 
tissue. In this regard, this study aims to evaluate the in vivo bone regeneration efficacy of 
TAT-BMP-2, which has been found to induce in vitro osteogenesis in previous studies by 
combining with fibrin, hydrogel, and PEEK to search for the most appropriate carrier 
system. 
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II. MATERIALS AND METHODS 
 
 
1. TAT-BMP-2 expression vector 
 
To insert the YGRKKRRQRRR domain of HIV-1 TAT fusion protein into the 
pRSET (Invitrogen, U.S.A) vector, PCR was done with T7 (5‘-CTCGAGTAATACGACT 
CACTATAGG-3') primer and 5‘-CATGGTGGATCCACCGCGGCGGCGCTGGCGGCG 
TTTCTTGCGGCCGTAGCCAAGCTTGGATCC-3' primer. The PCR product and 
pRSET vector were restricted by one unit of BamHI under 37℃ for two hours. After 
restriction, they were purified with a HiYield Gel Extraction kit (RBC, Taiwan). The 
pRSET-TAT vector was constructed by inserting the PCR product into the pRSET vector 
at the BamHI site. Human BMP-2 cDNA was acquired by PCR method, restricting Saos-
2 cell with primers, which have KpnI and HA sequences on C-terminal (5'-
GAGATTGGTACCATGGTGGCCGGGACCCGC-3', 5'-AATCTCGGTACCCTAAAGA 
GCGTAATCTGGAACATCGTATGGGTAGCGACACCCACAACC-3'). Amplified BMP-
2 were cloned into the KpnI site of the pREST-TAT vector. To insert N-terminal HA2 
peptides (GLFGAIAGFIENGWEGMIDG) of Influenza virus haemagglutinin-2, PCR 
was done with primers that have the T7 and BamHI sequences (5’-
GAGGCCGGATCCACCGTCTATCATTCCCTCCCAACCATTTTCTATGAAACCTGC
TATTGCGCCGAATAGGCCACCGCGGCGGCGCTGGCG-3') and pREST-TAT-BMP-
2-2-HA2 vectors were made. Additional Xpress and 6x histidine were added to tag the 
protein, separate them, and purify them by binding with Ni-NAT agarose (Figure 1).  
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Figure 1. TAT-BMP-2 vector map. HA2 was inserted to avoid entrapment of transduced 
protein.  
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2. TAT-BMP-2 protein expression and purification 
 
Recombinant protein was expressed through BL21 (DE3) Escherichia. coli 
(Invitrogen, U.S.A). The pTAT-BMP-2 vector was transformed to bacteria and streaked 
on a plate that contained 100µg/ml ampicillin. After incubating for over 16 hours, 
bacteria was collected by scraping and inoculated to 400ml 2 x YT (Q-Biogen, France) 
LB media, which contains 100µg/ml ampicillin (Sigma, U.S.A). Isopropyl-β-D-
thiogalactoside (Sigma, U.S.A) was added to reach a final concentration of 0.4mM when 
the value of OD600 was between 0.5 and 0.7. After four more hours of cultivation, 
centrifugation was done for 30 minutes under 5500rpm. Soluble lysis buffer (50mM Tris, 
pH8.0, 300mM NaCl, 20mM imidazole, pH8.0) 10ml was added to precipitation for 
resuspension, then sonication (amplitude 90, 60 seconds, two times) was done. Triton X-
100 was added to reach final concentration at 0.5 percent, and then centrifugation was 
done for 20 minutes under 4℃, 12000rpm. To denature the expressed protein, 10ml of 
inclusion body solution (8M urea, 50mM tris, pH8.0, 100mM NaCl) was added and 
dissolved for one hour at room temperature, and then centrifugation was done for 15 
minutes under 15000rpm. Supernatant reacted to 1ml of nickel-nitrilotriacetic acid (Ni-
NTA) agarose (Qiagen, Germany) for two hours under 4℃, which was substituted with 
binding buffer (8M urea, 50mM tris, pH8.0, 100mM NaCl, 20mM imidazole, pH8.0). 
Reacted Ni-NTA agarose was washed three times with 10ml of binding buffer and mixed 
with 500nM, 1mM imidazole binding buffer respectively for 20 minutes under 4℃. 
Afterward, centrifugation was done for one minute under 1000rpm to purify TAT-BMP-2. 
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The purified protein was aliquoted 100µl with adding 10 percent glycerol and stored at -
70℃. The concentration and purity of the protein was verified through SDS-PAGE gel 
using bovine serum albumin (BSA) and immunoblot analysis using anti-xpress. 
 
3. Cell culture and cell assay 
 
C3H10T1/2, osteosarcoma cell (OS), and gingival fibroblast (GF) were maintained 
in Dulbecco's MEM (DMEM) (Gibco, U.S.A) supplemented with 10 percent FBS, under 
37˚C, 5 percent CO2. For the in vitro cellular compatibility and viability assay, the 
fibroblast were kept in contact with the hydrogel, latex, and teflon for 72 hours. The cell 
proliferation assay was performed with cell counting kit-8 and MTT reagent while the 
fibroblast were kept in contact with the hydrogel, latex, and teflon.  
 
4. RT-PCR 
 
For monitoring Runt related transcription factor 2 (RUNX2), glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) expression, primer sequences for RT-PCR were: 
RUNX2 forward, 5-CTCTTCCCAAAGCCAGAGTG-3, RUNX2 reverse 5-CAGCGTC 
AACACCATCATTC-3, GAPDH forward, 5-TGAAGGTCGGAGTCAACGGATTT-3, 
GAPDH reverse, 5- CATGTGGGCCATGAGGTCCACCAC-3. 
The PCR reactions were performed at 60˚C, 30 cycles for runx2, and 58℃, 28 cycles 
for gapdh. Amplified products were visualized with a UV illuminator. 
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5. Immunoblot assay 
 
Western immunoblot analysis was performed to determine the expression of TAT-
BMP-2 following the conventional method. Primary antibodies were monoclonal anti-
xpress (Invitrogen, U.S.A), and polyclonal anti-Tubulin (Sigma, U.S.A). 
 
6. Acrylation of HA and preparation of hydrogel 
 
Procedures for manufacturing hydrogel were performed following previously 
reported methods (Kim J. et al., 2007). HA (0.25mmol, based on the repeating unit MW) 
was dissolved in 40 ml of distilled water and EDC (0.24g, 1.25mmol), HOBT (0.17g, 
1.25mmol) and adipic acid dihydrazide (ADH) (2.2g, 12.5mmol) were added to the 
solution. The EDC mediated the coupling reaction between the carboxyl group of HA and 
the hydrazide group of ADH with stirring, at room temperature for eight hours. HA–ADH 
was dialyzed against 100mM NaCl for two and a half days and distilled water for one day, 
using a dialysis membrane (Molecular weight cut off 14,000) (Spectra/Por; U.S.A). NAS 
(0.5g, 3mmol) was subsequently added to the HA–ADH solution. The reaction continued, 
with stirring, at room temperature for 12 hours. HA–ADH–NAS was dialyzed extensively 
against 100mM NaCl for two and a half days and distilled water for one day. The product 
was then lyophilized for three days to obtain solid acrylated HA (HA-Ac). The NMR 
spectra were obtained on a Mercury 200 NMR (200MHz) (Varian, U.S.A). D2O was used 
as a solvent for all the samples and the reported spectra represented an average of 64 
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scans. The degree of acrylation was calculated by comparing peaks from the acryl and 
methyl groups from the HA residue. For gel preparation, acrylated HA was dissolved in a 
triethanolamine-buffered solution (TEA; 0.3M, pH 8). PEG-SH4 (Molecular weight 
10,000), which contains soluble TAT-BMP-2 in planned concentration, was added as a 
cross-linker with the same molar ratio of the acryl and thiol groups. HA-based hydrogel 
was formed via a Michael-type addition reaction. The reaction mixture was incubated at 
37˚C for gelation. This hydrogel (5 percent weight of HA and PEG-SH4) was used in 
both in vitro and in vivo experiments. 
 
7. Animal experiment 
 
Four Beagle dogs (adult male weighting 13.0–14.0 kg) were purchased and fed in 
separate cages with free access to food and water. This animal study was approved by 
IACUC of Seoul National University Hospital Biomedical Research Institute. Animals 
were anesthetized using isoflurane (5 percent induce; 3 percent maintain) and 
administered subcutaneous atropine 0.05mg/kg, intravenous xylazine 2mg/kg, and zoletil 
5mg/kg immediately pre-operatively for pain mitigation. The electrocardiogram was 
monitored during operation. The surgical site was shaved and disinfected with 10 percent 
Betadine and subcutaneously injected with 2 percent lidocaine, containing 1:100,000 
epinephrine. A linear incision was made along the lateral thigh, and soft tissue and 
periosteum were reflected. 5mm diameter 6mm depth cylindrical defects were made in 
both femurs using a trephine bur while irrigating with saline. After extensive saline 
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irrgation to the defect site, the implant was placed into the defect, and the soft tissue was 
closed over the defect site using 3-0 vicryl and 3-0 nylon. Each subject was implanted 
with the following composition: first, fibrin and PEEK; second, fibrin, TAT-BMP-2 1µg, 
and PEEK; third, hydrogel; and fourth, hydrogel and TAT-BMP-2 2.5µg. Applied PEEK 
was cylindrical shape with bottom surface opened, 5mm diameter 6mm height 1mm wall 
thickness and opposing two 1mm diameter holes at the middle of lateral surface. All 
materials were gelated before insertion. Due to unintended lack of prepared PEEK, only 
two holes were made on left side of the second subject and no materials were inserted in 
the middle hole of right femur of the same subject. To avoid post-operative infection, 
intramuscular cefazolin 10mg/kg was injected once daily for three days. Radiologic 
examinations were performed to check the healing status of operation site every two 
weeks with BV Pulsera (Philips, Netherland).  
 
8. Radiological and histological analysis 
 
After allowing the defect to heal for five or six weeks, the animals were sacrificed 
by intravenous injection of zoletil and chloropotassium. The operative field was harvested 
and fixed in 10 percent formalin. Micro-computed tomography (microCT) analysis was 
performed using Skyscan 1076 (Skyscan, Belgium). Acquired images were processed in 
DICOM format and read by Simplant Crystal (Materialise, Belgium) to observe three-
dimensional structure. Bone density and volume were calculated and the spectrum of 
bone density was acquired by triangle view mode.  
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The bone pieces without a PEEK scaffold were then decalcified in 10 percent EDTA, 
pH 7 at room temperature, dehydrated in 70 percent ethanol and embedded in paraffin. 
The paraffin-embedded sections (5 micrometer) were stained with hematoxylin eosin and 
viewed using microscopy. Other bone pieces with PEEK scaffolds were embedded in 
methyl methacrylate, and stained with Villanueva. Digital images from stained sections 
and microCT were processed with SPOT version 4.5 (Diagnostic instrument Inc., U.S.A) 
and ImageJ version 1.45p (National Institutes of Health, U.S.A) to calculate the area of 
regenerated bone.  
 
9. Statistical analysis 
 
Density, area, volume of regenerated bone was obtained and compared each other. 
Area of the first and second subject was not calculated because their regeneration pattern 
was too scattered to calibrate. Statistical analysis was processed with SPSS 12.0 (SPSS, 
U.S.A) using Mann-Whitney test, a nonparametric statistical method. Critical p-value was 
0.05.  
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III. RESULTS 
 
 
1. Expression of TAT-BMP-2  
 
The TAT-BMP-2 vector was cloned by combining HIV-1 TAT,  and HA2 and 
expressed through the E.Coli BL21 (DE3) cell. The expressed protein was almost 
localized in the inclusion body. They were denatured by 8M urea to improve transduction 
efficiency and purified by Ni-NTA agarose through tagged histidine. Following the result 
of Coomassie Brilliant Blue staining, TAT-BMP-2 fusion protein was expressed at 52kDa 
size (Figure 2).  
 
1      2      3       4      5      6     7     8  9 10  11    12  13   14 
 
Figure 2. Expression of TAT-BMP-2 fusion protein. The red arrow indicates 52kDa size. Lane1: 
uninduction, Lane2: nduction, Lane3: soluble lysate, Lane4: supernatant, Lane5: insoluble 
lysate(inclusion body), Lane6: protein size marker, Lane7: 500mM Immidazole elution, Lane8: 
1M Immidazole elution, Lane9: Lane7 dialysis, Lane10: Lane8 dialysis, Lane11: BSA 
0.1mg/ml, Lane12: BSA 0.5mg/ml, Lane13: BSA 1mg/ml, Lane14: BSA 2mg/ml. 
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2. In vitro localization and function of TAT-BMP-2  
 
To verify the intracellular transduction, TAT-BMP-2 fusion protein was added in the 
culturing media of the C3H10T1/2 cell and expressed through the xpress tag. In the 
immunoblot analysis results, intracellular transduction of TAT-BMP-2 was higher than the 
negative control (Figure 3A). Also, the RT-PCR results showed that the mRNA 
expression level of RUNX2, a marker of initial stage osteogenesis, was higher in the TAT-
BMP-2 treated cell than in the negative control. This means that immature form TAT-
BMP-2 was transduced into intracellular space and then transformed to mature form, 
which led to osteogenesis (Figure 3B). 
 
TAT-BMP-2     - +
X-press
Tubulin
C3H10T 1/2
       
TAT-BMP-2    - +
Runx2
GAPDH
C3H10T 1/2
 
Figure 3. Internalization and function of TAT-BMP-2 fusion protein. A. Immunoblot 
analysis indicates intracellular transduction of TAT-BMP-2. B. TAT-BMP-2 induced cell 
shows RUNX2 expression. 
A. B. 
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3. In vitro biological properties of hydrogel 
 
3.1. Compatibility and viability of fibroblast 
To evaluate the biocompatibility of hydrogel, the fibroblast were maintained on 
hydrogel surface and observed by microscope after days three and seven. The fibroblast’s 
survival was observed in the results of both days three and seven (Figure 4A). The 
fibroblast were maintained on the surface of hydrogel, latex, teflon to test its own 
viability. Cellular proliferation and differentiation were more favorable in hydrogel than 
in teflon or latex (Figure 4B). 
 
 
Teflon HA gelLatex
 
Figure 4. In vitro evaluation of compatibility and viability. A. Compatibility of fibroblast 
on hydrogel. Left panel, day three, right panel, day seven. B. Viability on several 
polymers after 24 hours maintaining. 
 
A. 
B. 
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3.2. Proliferation of fibroblast on hydrogel 
The ability to proliferate was measured by cell counting kit-8 on days one, three, and 
seven. Absorbance at 450nm was increased as time goes by that the viability of living 
cells can be sustained on hydrogel (Figure 5A). Cytotoxicity was analyzed by MTT assay 
and hydrogel showed most favorable viability, in contrast to latex and Teflon (Figure 5B). 
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Figure 5. CCK-8 and MTT assay results. A. The result of CCK-8 assay meant activity 
of dehydrogenase of living cells. B. Cellular viability was observed through MTT assay.  
A. B. 
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4. Follow up radiograph 
 
Periodic radiographs were taken every two weeks after the animal experiments to 
evaluate healing status. Despite all defects, all subjects were radioluscent at two weeks. 
The subject with the TAT-BMP-2 and hydrogel composite showed notably higher 
radiopaqueness at four weeks after the operation than did the other subjects. The 
hydrogel-only subject and the TAT-BMP-2 hydrogel composite subject were given 
radiographs at five weeks again and sacrificed at that time due to their increased 
radiopaqueness. The fibrin-only and fibrin TAT-BMP-2 composite subjects with PEEK 
scaffold were given radiographs at the planned six weeks. However, no remarkable 
radiopaqueness was found (Figure 6). 
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Figure 6. Follow up radiographs. Decreased radioluscency means occurrence of bone 
regeneration. As there were no materials inserted at astronaut indicated region, the defect 
was excluded in analysis. 
* 
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5. MicroCT analysis 
 
After sacrificing all subjects, regions of interest with implanted materials on the 
femurs were cut and fixed in a 10 percent formalin solution. In microCT images, the 
subject with the TAT-BMP-2 hydrogel composite showed the highest attenuity at the 
operation site. Increased attenuation was extended to neighboring marrow space in the 
same subject. Only the hydrogel applied subject barely showed increased attenuation; the 
other two subjects showed just weak attenuation in limited marrow space (Figure 7). 
Fibrin+PEEK Fibrin+TAT-BMP1ug+PEEK
Hydrogel Hydrogel+TAT-BMP2.5ug
 
Figure 7. Micro CT images. Images were selected at the middle of defect. Attenuity was 
mostly increased at TAT-BMP-2 hydrogel composite applied subjects.  
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5.1. Density of regenerated bone 
 
By adjusting gradient color distribution following tissue density based on the 
Hounsfield unit, visualization and measuring bone density could be possible. Fat and soft 
tissue were orange, the inner cortex was green, and the outer cortex was red. The TAT-
BMP-2 hydrogel composite applied subject showed the most abundant, almost complete, 
bone regeneration, which had a similar density with the inner cortex and had only 
regenerated the outer cortex layer (Figure 8A). Only the hydrogel applied subject was 
found to have incomplete regeneration at each end side of the defect area. The fibrin-only 
and fibrin TAT-BMP-2 composite applied subjects showed a small amount of low density 
hard tissue with no statistical difference (p=0.097). The TAT-BMP-2 hydrogel composite 
applied subject showed the highest mean bone density on the defect area. Nevertheless, 
the difference between the hydrogel-only applied subject and the TAT-BMP-2 hydrogel 
composite applied subjects was 1.6, statistically not significant (p=0.724) (Figure 8B). 
 20 
 
Hydrogel Hydrogel+TAT-BMP2.5ug
Fibrin+PEEK Fibrin+TAT-BMP1ug+PEEK
 
27.6 28.52
40.62 42.16
0
10
20
30
40
50
Hydrogel+TAT
-BMP2.5ug
HydrogelFibrin+TAT-
BMP 1ug+PEEK
Fibrin+PEEK
 
Figure 8. Density analysis of regenerated bone. A. Gradient density view in software. 
Images were selected at the middle of defect. B. Mean bone density of regenerated bone.  
A. 
B. 
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5.2. Area of regenerated bone 
 
The area of regenerated bone on the defect was calculated by selecting the middle 
slice of the axial image. The total regenerated area was 810.17mm2 on the TAT-BMP-2 
hydrogel composite applied subject, and 504.17mm2 on the hydrogel-only applied subject. 
Regenerated area of these two subjects, hydrogel only applied subject and TAT-BMP-2 
hydrogel composite applied subject, showed a significant difference (p=0.009). The red 
labeled outer cortex was found only in the TAT-BMP-2 hydrogel composite applied 
subject and its area was 82mm2 (Figure 9).  
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Figure 9. Area analysis of regenerated bone. 
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5.3. Volume of regenerated bone 
 
A three-dimensional reconstruction model was made through volume rendering of 
multiple microCT axial images (Figure 10A). The hydrogel-only applied subject showed 
an unregenerated and empty appearance at the middle of the defect. In contrast, the TAT-
BMP-2 hydrogel composite applied subject showed a completely regenerated or almost 
blocked appearance on the top surface of the defect. The volume of the regenerated bone 
was 36.28mm3 in the TAT-BMP-2 hydrogel composite applied subject, which was 1.5 
times larger than the hydrogel-only applied subject (p=0.009). The fibrin-only and fibrin 
TAT-BMP-2 composite with PEEK scaffold showed 4.64mm3 and 4.72mm3, respectively 
(Figure 10B). The regeneration ratio, which confers the volume ratio between regenerated 
bone and defect, showed that the TAT-BMP-2 hydrogel composite applied subject had the 
highest regeneration efficiency, 58.44 percent (Figure 10C). 
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Figure 10. Volume analysis of regenerated bone. A. 3D reconstruction of femur of beagle. 
B. Volume comparison between subjects. C. Regeneration ratio. 
A. 
B. 
C. 
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6. Histological analysis 
 
Slides of subjects that did not contain PEEK were obtained through decalcification 
and hematoxylin-eosin staining. PEEK-containing subjects underwent undecalcification 
and Villanueva staining. In microscopic images, PEEK-containing subjects showed a 
little bone regeneration pattern in two regions. One was the open surface of PEEK-facing 
marrow space and the other was inside small holes at the middle of PEEK. The TAT-
BMP-2 hydrogel composite applied subject showed much more abundant regenerated 
bone than the hydrogel-only applied subject. In addition, the TAT-BMP-2 hydrogel 
composite applied subject showed regeneration of continuity of the outer cortex and 
periosteum, an increase of the Harversian system, and osteocyte and periosteal reaction. 
Regeneration was extended to the adjacent marrow portion and the regenerated bone had 
a more mature, dense structure (Figure 11). 
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Figure 11. Histlogical analysis of regenerated bone. A. Fibrin with PEEK, x10, B. Fibrin, 
TAT-BMP-2 1ug with PEEK, x10, C. Hydrogel, x10, D. Hydrogel, TAT-BMP-2 2.5ug, 
x10, E. Hydrogel, x40, F. Hydrogel, TAT-BMP-2 2.5ug, x40.  
 
A. B. 
C. D. 
E. F. 
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IV. DISCUSSION 
 
Regenerating or repairing damaged bone tissue due to various causes is a significant 
challenge in dentistry, orthopedics, and neurosurgery. Graft materials for defect areas are 
divided into autograft, allograft, alloplast, and xenograft, with autograft being considered 
the most promising therapy (Myeroff and Archdeacon, 2011; Nauth et al., 2011). 
However, shortages such as limited graft accessibility, donor site morbidity, and increased 
costs are driving research about new materials for bone repair and regeneration (Bishop 
and Einhorn, 2007; Geiger et al., 2003).  
Current biological strategies for bone regeneration with de novo synthesized 
materials are devided in three ways (Rose et al., 2004): gene therapy, the transduction of 
genes encoding cytokines with osteogenic capacity into cells at repair sites; stem cell 
therapy, the transplantation of cultured osteogenic cells derived from host bone marrow; 
and protein therapy, the application of osteoinductive growth factors. Because gene and 
stem cell based therapy have yet to show definite results (Kimelman et al., 2007), protein 
therapy can be accepted as the most practical and promising method.  
Several studies have tried to regenerate bone in an in vivo environment using 
exogenous BMPs and some have received Food and Drug Administration (FDA) approval 
for merchandising through pre-clinical examinations. Currently, two rhBMP-based 
commercial products, INFUSE (rhBMP-2, Medtronics, Minneapolis, MN, U.S.A) and OP-
1 (rhBMP-7, Stryker Biotech, Hopkinton, MA, U.S.A) have received FDA approval for 
several surgical applications. INFUSE uses an absorbable collagen sponge (ACS) and OP-1 
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uses carboxymethylcellulose sodium as a carrier. In addiontion, Cowell BMP&Boss 
(Cowell Medi, Korea) delivers rhBMP coated in biphasic calciumphosphate/hydroxy 
apatite. But, in spite of the splendid developments in rhBMP therapy, it is still obscure 
and questionable in two ways: first, there have been problems in combination with 
current carriers, and second, the supraphysiological dosage of rhBMP for desired 
ostoinductive effect. Currently, rhBMP-2 is supplied with an ACS carrier or a biphasic 
calciumphosphate/hydroxy apatite in which rhBMP-2 is coated. Although the carrier’s 
ability to release biologic factors in a controlled manner is one of the most important 
parts of tissue engineering, current carriers are still insufficient in this aspect and cause a 
short in vivo half life for rhBMP-2. In fact, Hollinger et al. indicated that due to initial 
burst release, less than 5 percent of rhBMP remains within the collagen sponge at two 
weeks in vivo (Hollinger et al., 1998). Specifically, since the collagen sponge lacks 
mechanical integrity, the local concentration of rhBMP-2 can increase to undesirably high 
levels as the sponge is compressed by overlying muscles and other tissue. Also, since 
rhBMP-2 is physically entrapped in the collagen matrices and depend on matrix 
degradation for release, their release kinetics are unpredictable and difficult to control 
(Tan et al., 2007). Because a lack of controlled releasing triggers the second problem, 
rhBMP-2’s minimal concentration for in vivo bone regeneration increases the chance that 
clinical complications such as soft tissue edema, erythema, local inflammation, 
heterotropic ossification, immune response, or osteoclastic activity might arise by 
supraphysiologic concentration (Lo et al., 2012). Also, rhBMP-2 from CHO cells or 
bacteria are lacking in post-translational modification, their biologic effect is depressed or 
insufficient (Itoh et al., 1999). So the actual dosage for clinical application (milligram 
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level) became several million times more elevated than the endogenous BMP level 
(nanogram level), which led to a considerable rise in cost (Haidar et al., 2009; Luginbuehl 
et al., 2004).  
To solve these current problems, a previous study manufactured an intracellular 
BMP delivery system using PTD (Kim NH., 2007). Kim purified TAT-BMP-2 from E. 
Coli., denatured it to improve transduction efficiency, and demonstrated in vitro 
osteogenesis inducibility. To prove TAT-BMP-2’s ability in vivo, its soluble property 
causing rapid clearance should be compensated with biomaterial that are able to retain 
and sequester biologic factors for elevating efficacy and lowering protein dosage. 
Fibrin and hydrogel were selected as carriers for this experiment because they are 
injectable in clinical applications and natural polymers that guarantee biocompatibility 
degrading without foreign body reactions. However, as fibrin degrades more rapidly than 
hydrogel by proteolytic activity, fibrin is hard to acquire controlled releasing 
pharmacokinetics. In addition, hydrogel can be manufactured by several methods that 
results in different specifications of polymerization, gelation, and degradation (Toh et al., 
2012). Hydrogels also have characteristics to induce vasculogenesis and angiogenesis, 
which are beneficial in osteogenesis (Hanjaya-Putra et al., 2012). 
A PEEK scaffold was used in this experiment to isolate containing materials from 
external environment in evaluating osteogenesis. The two subjects with PEEK showed a 
little amount of regeneration from the marrow space and the small holes in the middle of 
the PEEK body. Though TAT-BMP-2 fibrin composite induced a little more abundant 
matured regeneration, no significant differences were found between fibrin-only applied 
subject. Also, the quantity and quality of regenerated bone in PEEK applied subjects were 
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inferior than the subjects which did not contain PEEK. Hence, even if the TAT-BMP-2 
fibrin composite induced superior bone regeneration than the fibrin-only applied subject 
under isolated condition by PEEK, the inferiority of their entire regeneration efficacy than 
without PEEK applied subjects are caused not only the low porosity of the PEEK design 
but also inadequacy of fibrin as a slow degrading-releasing carrier..  
Though the hydrogel-only application induced partial bone regeneration, the TAT-
BMP-2 hydrogel composite showed more effective regeneration than the hydrogel 
alone. The TAT-BMP-2 hydrogel composite induced one and a half times the 
regeneration in area, volume analysis, and restoration of continuity of the outer cortex 
with favorable bone density. Also, the quantity and quality of regenerated bone were 
superior to that of the hydrogel-only applied subject. This is practically originated by 
TAT-BMP-2’s in vivo osteogenesis inducibility based on proper chemical binding 
between TAT-BMP-2 and the hydrogel carrier that makes controlled BMP release 
during slow carrier degradation.  
Besides the TAT-BMP-2 hydrogel composite’s active bone regeneration, this 
combination suggested another advantage in practical trials. The concentration of TAT-
BMP-2 in this experiment was in micrograms, which is a much lower concentration than 
that of currently merchandising rhBMP-2 (mg/ml level). As previous in vitro study 
demonstrated that the minimal concentration for BMP-2 secretion was 1µg/ml (Kim NH., 
2007), the quantity of TAT-BMP-2 for isolated condition was set at 1µg and 2.5µg for 
TAT-BMP-2 hydrogel composite considering diffusion. Consequently, TAT-BMP-2 
indicated a new way to overcome several complications by supraphysiologic concentration 
of rhBMP-2. 
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Though TAT-BMP-2 is a still an incomplete molecule that needs to be improved, its 
bone regenerating ability is demonstrated both in vitro and in vivo. To continue making 
advances, and to ultimately get approval for clinical use, more advanced animal studies in 
special functional surgery with lower dosages are needed in the near future. 
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V. CONCLUSION 
 
1. TAT-BMP-2 fibrin composite induced superior bone regeneration than the fibrin-only 
applied subject under isolated condition by PEEK, but statistically not significant. 
2. Hydrogel-only application induced partial bone regeneration. 
3. TAT-BMP-2 hydrogel composite caused bone regeneration superior to that of hydrogel-
only application in area and volume analysis (p<0.05). 
4. TAT-BMP-2 hydrogel composite only induced regeneration of continuity of the outer 
cortex and showed a more mature, dense structure than hydrogel-only application. 
5. TAT-BMP-2 hydrogel composite decreased dosage for in vivo bone regeneration by 
1/1000 of the conventional dosage of rhBMP-2. 
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ABSTRACT (IN KOREAN) 
 
TAT-BMP-2와 Hydrogel 복합체의  
생체 내 골 재생 능력 평가 
 
 
<지도교수 육 종 인> 
연세대학교 대학원 치의학과 
손 규 호   
 
  노령화 사회로 진행됨에 따라 치조골 소실 및 골다공증 환자가 증가하고 있
으며, 골 재생의 필요성은 점차 증가하고 있으나 현재까지 명확한 해결책은 
부족한 실정이다. 외인성 골 형성 유도물질이 효과적으로 작용하기 위해서는 
충분한 생체활성을 지녀야 하며 재료의 방출을 조절할 수 있는 전달체와 생물
학적, 화학적, 기계적 조화를 이루어야 한다. 생물학적 골재생을 위해 재조합
골형성단백질 (rhBMP-2)가 임상적으로 시도되고 있으나 낮은 효율성을 보이는 
것으로 보고되고 있다. 
 
  본 연구에 사용된 TAT-BMP-2는 기존의 rhBMP-2와는 다른 비활성 폴리펩타이
드 형태로, rhBMP-2가 BMP 수용체와 결합하여 활성을 나타내는 활성 단백질인 
것과는 달리, BMP 수용체와는 무관하게 세포 내로 이송되는 특징을 지니고 있
다. 하이드로겔은 결합조직 세포외기질의 주요 성분인 하이알루론산을 원료로 
합성되며 생체적합성이 우수하고 생흡수와 동시에 약물 방출 속도를 조절할 
수 있는 특성을 지니고 있다. 본 연구는 in vitro에서 합성한 TAT-BMP-2를 피
브린/Polyether ether ketone(PEEK), 하이드로겔 등의 전달체와 조합하여 비
글견 대퇴골에서의 골 재생 효과를 방사선학적, 조직학적으로 관찰하고자 하
였으며, 다음과 같은 결과를 얻었다. 
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1. PEEK에 의해 고립된 환경에서 TAT-BMP-2 피브린 복합체는 피브린만 적용한 
경우보다 양호한 골 재생을 보이지만 유의미한 차이를 나타내지는 않는다. 
2. 하이드로겔만 적용한 경우에도 부분적인 골 재생이 관찰된다. 
3. 하이드로겔 단독으로 사용한 경우보다 TAT-BMP-2와 하이드로겔 복합체를 
사용하였을 때, 생체 내 골 재생이 면적, 부피 면에서 모두 150% 가량 우
수하였다. 
4. TAT-BMP-2 하이드로겔 복합체를 사용했을 때에만 조직학적으로 외피질골의 
연속성이 회복되었으며 하이드로겔만 사용한 경우보다 성숙, 치밀한 구조
가 관찰된다. 
5. TAT-BMP-2 하이드로겔 복합체는 생체에서 골 재생을 위해 요구되는 BMP의 
농도를 rhBMP-2의 1/1000 수준으로 낮출 수 있다. 
 
  이상의 결과에서 TAT-BMP-2와 하이드로겔 복합체는 생체 내에서 효과적인 
골 재생 효과를 유도하는 것을 알 수 있었으며, 이러한 효과는 비활성 폴리펩
타이드 형태의 TAT-BMP-2에 의한 고효율의 단백질 형성 및 하이드로겔에 의한 
단백질의 조절 분비에 의한 것으로 사료된다. 
 
 
 
 
 
 
 
 
 
 
 
 
 
핵심어 : 단백질 전달영역, HIV-1 TAT, 골형성단백질, 하이드로겔 
